Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma’s race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
